Xalkori(Pfizer)success in Phase III trial in ALK-positive advanced NSCLC - 21-Jun-2012

The PROFILE 1007 study met its primary endpoint, demonstrating that Xalkori (crizotinib) from Pfizer significantly improved progression-free survival when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). PROFILE 1007 is the first randomized Phase III study in ALK-positive advanced NSCLC patients. Xalkori received an accelerated approval by the FDA for the treatment of locally advanced or metastatic NSCLC that is ALK-positive as detected by an FDA-approved test.

Related News

Phase III study of Tomtovok (Boehringer) meets endpoint for NSCLC

IDMC halts Phase III study of Vargatef (Boehringer) in NSCLC

FDA approves Tarceva (Genentech/Astellas) for NSCLC as detected by cobas EGFR Mutation Test

NICE rejects Xalkori (Pfizer) for treatment of Non Small Cell Lung Cancer

CRLX 101 (Cerulean Pharma) fails in Phase II trial for NSCLC

NICE rejects extended use of Alimta (Eli Lilly) in NSCLC

Phase III trial of Stimuvax (Merck Serono) fails to meet primary endpoint in patients with NSCLC

New Phase II trial shows combination treatment with selumetinib (AstraZeneca) has promise for patients with NSCLC

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

Fasiglifam (Takeda) success in Phase III trial for treatment of Type 2 Diabetes

20 May 2013

Takeda Pharmaceutical Company Limited announced results of a Phase III clinical trial (CCT-003) of fasiglifam (TAK-875) for the treatment...

Read full article

NICE recommends Betmiga (Astellas) for patients with Overactive Bladder

20 May 2013

The National Institute for Health and Care Excellence ( NICE) in England and Wales has issued final draft guidance recommending Betmiga...

Read full article